Skip to main content
Home logo

User account menu

Log inSearch

Main navigation

  • Home
  • Data Sources
  • Studies
  • Institutions
  • Networks
  • What's new
  • Support
  1. Home

Subscribe to An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of rivaroxaban (XARELTO®) initiated in secondary care for the prevention of atherothrombotic events in patients who have had acute coronary syndrome in England and Wales (ROSE ACS)

HMA-EMA Catalogues of real-world data sources and studies

Privacy

Privacy policy
Cookies
Legal notice

Contact

Contact us